Search

Search Results

• PO:06:081 | Safety of JAK inhibitors compared to non-TNF-targeted biologic therapies in rheumatoid arthritis patients who are inadequate responders to TNF inhibitors Lorenzo Di Luozzo¹, Alessandro Giollo¹, Mariangela Salvato¹, Francesca Frizzera¹, Kiren Khalid¹, Margherita Zen¹, Andrea Doria¹ | ¹Azienda ospedaliera universitaria di Padova, unità di Reumatologia, Padova, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2298

  61

• Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide

  M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli

  94-103

  https://doi.org/10.4081/reumatismo.2004.94

  1550

  PDF: 1008

• PO:36:252 | Long-Term Outcomes of Patients with Takayasu Arteritis in the Era of Biological Agents: a Multicenter International Study Alessandro Tomelleri¹, Durga Prasanna Misra², Fatma Alibaz-Oner³, Chiara Marvisi⁴, Chiara Calabrese¹, Upendra Rathore², Aysegul Avcu³, Adele Del Giudice⁴, Elisabetta Olivi⁴, Caterina Ricordi⁴, Corrado Campochiaro¹, Elena Baldissera¹, Marco Matucci-Cerinic¹, Haner Direskeneli³, Carlo Salvarani⁴, Lorenzo Dagna¹ | ¹IRCCS Ospedale San Raffaele, Unità di Immunologia, Reumatologia, Allergologia e Malattie Rare Milano, Italy; ²Sanjay Gandhi Postgraduate Institute of Medical Sciences SGPGIMS, Clinical Immunology and Rheumatology Lucknow Country, India; ³Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology Istanbul, Turkey; ⁴Azienda USL-IRCCS di Reggio Emilia, Unità di Reumatologia Reggio Emilia, Italy

  Società Italiana di Reumatologia

  18-03-2026

  https://doi.org/10.4081/reumatismo.2025.2389

  37

• Kidney involvement in rheumatoid arthritis

  A. Icardi, P. Araghi, M. Ciabattoni, U. Romano, P. Lazzarini, G. Bianchi

  76-85

  https://doi.org/10.4081/reumatismo.2003.76

  5889

  PDF: 7785

• PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato¹, Giacomo Cozzi¹, Mariagrazia Lorenzin¹, Mariangela Salvato¹, Alessandro Giollo¹, Bernd Raffeiner¹, Antonia Calligaro¹, Teresa Del Ross¹, Sara Bindoli¹, Margherita Zen¹, Paolo Sfriso¹, Andrea Doria¹, Roberta Ramonda¹. | ¹UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2003

  192

• New classification criteria for rheumatoid arthritis

  C.A. Scirè, R. Caproali

  159-162

  https://doi.org/10.4081/reumatismo.2010.159

  2662

  PDF: 9075

• Ultrasonographic assessment of the response to Etanercept treatment in patients with rheumatoid arthritis

  A. Iagnocco, C. Perella, F. Ceccarelli, E. Tripodo, C. Alessandri, L. Magrini, G. Valesini

  233-238

  https://doi.org/10.4081/reumatismo.2006.233

  1146

  PDF: 1076

• PO:13:188 | Menstrual alterations among women with rheumatoid arthritis: a comparative study across treatment modalities with focus on JAK inhibitors Angelica Napoletano¹, Francesca Arezzo², Marco Fornaro¹, Giuseppe Lopalco¹, Gennaro Cormio², Vincenzo Venerito¹, Florenzo Iannone¹. | ¹University of Bari, Rheumatology Unit Department of Precision and Regenerative Medicine, Jonica Area, Bari; ²Gynecologic Oncology, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2029

  378

• The risk/benefit profile of biologic drugs in real-world rheumatology practice. From ANTARES to MonitorNet

  P. Sfriso, F. Salaffi, S. Bombardieri, B. Canesi, C.M. Montecucco, S. Todesco

  77-84

  https://doi.org/10.4081/reumatismo.2008.77

  1997

  PDF: 911